Striatal tyrosine hydroxylase-positive neurons are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice

[1]  Qin Li,et al.  Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA–Induced Dyskinesia , 2016, Biological Psychiatry.

[2]  W. Oertel,et al.  Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation , 2014, Journal of Chemical Neuroanatomy.

[3]  F. Turkheimer,et al.  Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.

[4]  C. Depboylu.  Non-serine-phosphorylated tyrosine hydroxylase expressing neurons are present in mouse striatum, accumbens and cortex that increase in number following dopaminergic denervation , 2014, Journal of Chemical Neuroanatomy.

[5]  Eduardo D. Martín,et al.  L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function , 2012, Neurobiology of Disease.

[6]  M. Luquin,et al.  Chronic Levodopa Administration Followed by a Washout Period Increased Number and Induced Phenotypic Changes in Striatal Dopaminergic Cells in MPTP-Monkeys , 2012, PloS one.

[7]  P. Petersson,et al.  Levodopa-Induced Dyskinesia Is Strongly Associated with Resonant Cortical Oscillations , 2012, The Journal of Neuroscience.

[8]  S. Dunnett,et al.  Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: Predicting l-DOPA-induced dyskinesia , 2012, Behavioural Brain Research.

[9]  E. Bézard,et al.  Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia , 2011, Neuroscience.

[10]  G. Fisone,et al.  L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission , 2011, Front. Behav. Neurosci..

[11]  J. Rothwell,et al.  Abnormal bidirectional plasticity-like effects in Parkinson's disease. , 2011, Brain : a journal of neurology.

[12]  W. Oertel,et al.  Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease , 2011, Journal of Neuroimmunology.

[13]  M. Cenci,et al.  Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease , 2011, Neurobiology of Disease.

[14]  A. Parent,et al.  Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia , 2010, Neurobiology of Disease.

[15]  Erwan Bezard,et al.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa–induced dyskinesia , 2010, Proceedings of the National Academy of Sciences.

[16]  L. Descarries,et al.  Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia , 2010, Annals of neurology.

[17]  D. Kirik,et al.  Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA–induced dyskinesia in rats , 2010, Proceedings of the National Academy of Sciences.

[18]  R. Watts,et al.  Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements , 2010, The Journal of Neuroscience.

[19]  B. Bioulac,et al.  Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease , 2010, Neurobiology of Disease.

[20]  M. Cenci,et al.  l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia , 2010, Journal of neurochemistry.

[21]  Qin Li,et al.  Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease , 2009, Biological Psychiatry.

[22]  A. Björklund,et al.  Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.

[23]  C. Barnum,et al.  The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats , 2009, Synapse.

[24]  M. L. de Ceballos,et al.  Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by l‐DOPA , 2008, The European journal of neuroscience.

[25]  A. Parent,et al.  l-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys , 2008, Journal of Chemical Neuroanatomy.

[26]  A. Björklund,et al.  Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2007, The Journal of Neuroscience.

[27]  A. Parent,et al.  Dopaminergic neurons intrinsic to the striatum , 2007, Journal of neurochemistry.

[28]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[29]  M. Cenci,et al.  The “motor complication syndrome” in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration , 2007, Behavioural Brain Research.

[30]  M. Andersson,et al.  Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with ΔFosB , 2007, Neuroscience.

[31]  J. Stellar,et al.  c-Fos and ΔFosB expression are differentially altered in distinct subregions of the nucleus accumbens shell in cocaine-sensitized rats , 2006, Neuroscience.

[32]  A. Parent,et al.  The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. , 2006, Brain : a journal of neurology.

[33]  J A Obeso,et al.  Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. , 2006, Brain : a journal of neurology.

[34]  M. Schäfer,et al.  Three Types of Tyrosine Hydroxylase-Positive CNS Neurons Distinguished by Dopa Decarboxylase and VMAT2 Co-Expression , 2006, Cellular and Molecular Neurobiology.

[35]  E. Hirsch,et al.  New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. , 2006, Brain : a journal of neurology.

[36]  N. Pavón,et al.  ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, Biological Psychiatry.

[37]  Peter Brown,et al.  Basal ganglia local field potential activity: Character and functional significance in the human , 2005, Clinical Neurophysiology.

[38]  G. Linazasoro.  New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. , 2005, Trends in pharmacological sciences.

[39]  G. Fisone,et al.  Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.

[40]  K. Nagata,et al.  Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA , 2005, Brain Research.

[41]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[42]  H. Lindgren,et al.  A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function , 2004, Neurobiology of Disease.

[43]  J. Benoit,et al.  Striatal tyrosine hydroxylase immunoreactive neurons are induced by l-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats , 2004, Neuroscience Letters.

[44]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[45]  R. P. Maguire,et al.  Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications , 2004, Journal of Neural Transmission.

[46]  J. Labandeira-Garcia,et al.  Localization and functional significance of striatal neurons immunoreactive to aromatic l-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models , 2003, Brain Research.

[47]  Peter Brown,et al.  Oscillatory Local Field Potentials Recorded from the Subthalamic Nucleus of the Alert Rat , 2002, Experimental Neurology.

[48]  A. Björklund,et al.  l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.

[49]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[50]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[51]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[52]  G. Donnan,et al.  New dopaminergic neurons in Parkinson's disease striatum , 2000, The Lancet.

[53]  D. D. Di Monte,et al.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.

[54]  M. Andersson,et al.  Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.

[55]  S. Totterdell,et al.  Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine‐depleting lesions , 1999, The European journal of neuroscience.

[56]  D. S. Zahm,et al.  Functional‐anatomical Implications of the Nucleus Accumbens Core and Shell Subterritories , 1999, Annals of the New York Academy of Sciences.

[57]  T. Suda,et al.  Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.

[58]  Mark J. West,et al.  Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias , 1999, Trends in Neurosciences.

[59]  R. Turner,et al.  Dopaminergic Neurons Intrinsic to the Primate Striatum , 1997, The Journal of Neuroscience.

[60]  K. Vrana,et al.  Intricate Regulation of Tyrosine Hydroxylase Activity and Gene Expression , 1996, Journal of neurochemistry.

[61]  R. Arai,et al.  l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study , 1995, Neuroscience Letters.

[62]  L. Iacovitti,et al.  Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons , 1995, Brain Research.

[63]  A. Kelley,et al.  Oral stereotypy induced by amphetamine microinjection into striatum: An anatomical mapping study , 1994, Neuroscience.

[64]  E. Prinssen,et al.  Evidence for a role of the shell of the nucleus accumbens in oral behavior of freely moving rats , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  Xin-Min Li,et al.  Decarboxylation ofl-Dopa by cultured mouse astrocytes , 1993, Brain Research.

[66]  I. Kanazawa,et al.  Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum , 1992, FEBS letters.

[67]  T. Hattori,et al.  Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat , 1989, Neuroscience Letters.

[68]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[69]  P. Emson,et al.  Enzymes Related to Monoamine Transmitter Metabolism in Brain Microvessels , 1980, Journal of neurochemistry.

[70]  R. Wurtman,et al.  Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonism , 1980, Annals of neurology.

[71]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[72]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[73]  M. Ugrumov.  Brain neurons partly expressing dopaminergic phenotype: location, development, functional significance, and regulation. , 2013, Advances in pharmacology.

[74]  M. Delong,et al.  Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa , 2012, Neuropsychopharmacology.

[75]  A. Lees,et al.  Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. , 2011, Journal of Parkinson's disease.

[76]  T. Schallert,et al.  Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .